Welcome to our dedicated page for CALCIMEDICA SEC filings (Ticker: CALC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CalciMedica, Inc. (CALC) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, clinical-stage biopharmaceutical company focused on CRAC channel inhibition therapies, CalciMedica uses its filings to report financial results, corporate actions, and material developments related to programs such as its Auxora™ clinical trials in acute kidney injury (AKI) with respiratory failure and acute pancreatitis (AP).
Key documents available through EDGAR and summarized here include Form 10-K annual reports and Form 10-Q quarterly reports, which provide detailed discussions of CalciMedica’s business, risk factors, pipeline status, and financial condition. Form 8-K current reports capture specific events such as quarterly earnings press releases, amendments to equity incentive plans approved at the annual meeting, and changes to at-the-market equity offering capacity under the company’s agreement with H.C. Wainwright & Co.
Investors can also monitor S-3 and S-8 registration statements and related exhibits that describe securities offerings and share-based compensation plans, as well as any Form 4 insider transaction reports that may be filed by directors and officers. These filings help clarify how CalciMedica finances its clinical-stage operations, including the use of at-the-market offerings and a disclosed credit facility, and how equity incentives are structured for employees and leadership.
Stock Titan enhances access to these documents with AI-powered summaries that highlight key points from lengthy filings, such as changes in cash runway commentary, updates on the KOURAGE trial, or modifications to capital-raising programs. Real-time updates from EDGAR ensure that new CalciMedica filings appear quickly, while structured views of 10-Ks, 10-Qs, 8-Ks, registration statements, and Form 4 reports allow users to focus on the specific regulatory information most relevant to their analysis of CALC.
CalciMedica, Inc. Chief Financial Officer Stephen Bardin received a grant of employee stock options covering 67,728 shares of common stock at an exercise price of $0.585 per share. Beginning April 1, 2026, 1/48th of the option shares vest in equal monthly installments over four years, with vesting starting only after the company files a Form S-8 for shares added under its 2023 Equity Incentive Plan.
CalciMedica, Inc. reported that Chief Medical Officer Sudarshan Hebbar received an employee stock option grant covering 91,173 shares of common stock with an exercise price of $0.585 per share. All 91,173 options are held directly after this grant.
Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over four years, and no shares vest until the company files a Form S-8 covering shares added under its 2023 Equity Incentive Plan evergreen provision.
CalciMedica, Inc. reported that Chief Business Officer and 10% owner Eric W. Roberts received an option grant covering 83,358 shares of common stock. The employee stock option has an exercise price of $0.585 per share and expires on April 4, 2036.
According to the vesting terms, beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over four years. No shares will vest until the company files a Form S-8 covering shares automatically added under its 2023 Equity Incentive Plan pursuant to an annual evergreen provision.
CalciMedica, Inc. reported that President and COO Michael J. Dunn received an employee stock option grant for 65,124 shares of common stock at an exercise price of $0.585 per share. The option expires on April 4, 2036 and vests in monthly installments over four years, beginning April 1, 2026, after a Form S-8 is filed to cover shares added under the company’s 2023 Equity Incentive Plan evergreen provision.
CalciMedica, Inc. reported that Chief Scientific Officer Kenneth A. Stauderman received an employee stock option grant for 65,124 shares of common stock at an exercise price of $0.585 per share. The option expires on April 4, 2036.
Beginning April 1, 2026, 1/48 of the option vests in equal monthly installments over four years. Vesting will not begin until a Form S-8 is filed covering shares automatically added on January 1, 2026 under the company’s 2023 Equity Incentive Plan evergreen provision.
CalciMedica, Inc. director and chief executive officer Rachel A. Leheny received a grant of 148,482 employee stock options to buy common stock at an exercise price of $0.585 per share. The options expire on April 4, 2036.
Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over four years. No shares will vest until a Form S-8 is filed for shares automatically added to the company’s 2023 Equity Incentive Plan on January 1, 2026.
CalciMedica, Inc. reported that Nasdaq has notified the company it no longer meets multiple continued listing standards for the Nasdaq Capital Market. The market value of its listed securities has stayed below the $35,000,000 minimum for 30 consecutive business days, triggering a 180-day cure period ending on September 9, 2026.
The company can regain compliance by meeting any of the alternatives: stockholders’ equity of at least $2,500,000, market value of listed securities of at least $35,000,000, or net income from continuing operations of $500,000 in the relevant periods. Separately, Nasdaq also notified CalciMedica that its common stock has traded below the $1.00 minimum bid price for 30 consecutive business days, starting another 180-day grace period through September 14, 2026 to restore the bid price for at least 10 consecutive business days.
The stock continues to trade on Nasdaq under the symbol CALC, but failure to regain compliance could lead to delisting. The company plans to monitor the requirements and is considering options such as a reverse stock split, while noting there is no assurance it will successfully regain or maintain compliance.
CalciMedica, Inc. has filed a shelf registration prospectus to offer, from time to time, up to $125,000,000 of common stock, preferred stock, debt securities and/or warrants.
The filing states offerings will be made in one or more offerings with specific terms provided in prospectus supplements; sales are described as issuer offerings and proceeds are for the issuer’s general corporate purposes. The company’s common stock trades on Nasdaq under the symbol CALC (last reported sale $0.507 per share on March 2, 2026).
CalciMedica, Inc. is a clinical-stage biopharmaceutical company developing calcium release-activated calcium (CRAC) channel inhibitors, led by its intravenous candidate Auxora for acute pancreatitis and other critical inflammatory conditions. The company has never generated product revenue and discloses a history of net losses with substantial doubt about its ability to continue as a going concern without significant additional capital.
Auxora has shown encouraging Phase 2 data in acute pancreatitis, severe COVID-19 pneumonia, and pediatric asparaginase-induced pancreatic toxicity, and CalciMedica plans to finalize a pivotal program design in acute pancreatitis in the first half of 2026. A Phase 2 trial in acute kidney injury with acute hypoxemic respiratory failure (KOURAGE) was discontinued in January 2026 after a mortality imbalance, though independent reviewers did not find drug-related toxicity, and the company will discuss future development with the FDA.
CalciMedica is also advancing CM5480, an Orai1-selective CRAC inhibitor, toward an anticipated 2027 IND for pulmonary arterial hypertension and is exploring oral CRAC inhibitors in chronic inflammatory and immunologic diseases. It relies on third-party manufacturers, faces intense competition in inflammation and critical care, and highlights extensive scientific and development risks alongside potential opportunities for strategic partnerships.